Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major Shareholder Sells $1,595,406.00 in Stock

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) major shareholder Global Strategic Fund I. Venbio sold 153,700 shares of the stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $10.38, for a total value of $1,595,406.00. Following the completion of the transaction, the insider now directly owns 2,652,133 shares of the company’s stock, valued at approximately $27,529,140.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of NASDAQ CMPI opened at $10.37 on Thursday. The stock’s 50 day moving average price is $4.81 and its two-hundred day moving average price is $3.79. Checkmate Pharmaceuticals, Inc. has a 52-week low of $2.00 and a 52-week high of $10.48.

Checkmate Pharmaceuticals (NASDAQ:CMPI – Get Rating) last announced its quarterly earnings results on Tuesday, March 29th. The company reported ($0.62) earnings per share for the quarter. As a group, equities research analysts predict that Checkmate Pharmaceuticals, Inc. will post -3.14 EPS for the current fiscal year.

An institutional investor recently bought a new position in Checkmate Pharmaceuticals stock. Millennium Management LLC purchased a new position in shares of Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,633 shares of the company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 74.56% of the company’s stock.

Several analysts have issued reports on the company. Zacks Investment Research upgraded Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. BTIG Research cut Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, April 20th.

About Checkmate Pharmaceuticals (Get Rating)

Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.

Read More